Methods and devices for localizing compositions
Electromagnetic forces are used to control the dispersion of injectable materials post-injection, improving localization and reducing adverse effects by applying attractive or repulsive forces, thus enhancing the precision and efficacy of neurotoxin and dermal filler treatments.
Patent Information
- Application Number
- JP2021549162
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-24
- Filing Date
- 2020-02-20
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-02-20
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 807,929, filed February 20, 2019, No. 62 / 812,228, filed February 28, 2019, and No. 62 / 878,030, filed July 24, 2019, each of which is incorporated by reference in its entirety herein.
[0002] The present invention relates to systems, methods and devices for localizing a material administered to a mammal, for example via injection. [Background technology]
[0003] Injections are a common method of introducing materials (e.g., therapeutic materials) into patients. However, such injections carry the risk of undesired dispersion or dissipation of the material beyond the desired treatment site. For example, adverse effects may occur if the injection of a neurotoxin spreads beyond the treatment site. In the case of injections into the frown lines or "crow's feet", drooping of the eyes or "ptosis" may occur. Injections into the head may result in neck weakness or difficulty swallowing. Additionally, if the injected material spreads from the desired treatment site, it may increase the immune response. In the case of dermal filler injections, the injected material may spread beyond the treatment site, causing undesired cosmetic effects, for example, when treating the lips or cheekbones.
[0004] Electrical stimulation can affect the movement of molecules, biological agents, etc., and it is known that electromagnetic forces, including electric currents, charges, electric fields, magnetic fields, etc., can be used therapeutically. For example, iontophoresis is the process of transdermal drug delivery by the use of a voltage gradient over the skin. Molecules (e.g., drugs or biological agents) are transported across the stratum corneum by electrophoresis (movement of dispersed particles relative to a fluid under the influence of a spatially uniform electric field) and electroosmosis (movement of a liquid induced by an electric potential applied across a porous material). During iontophoresis, a small electric current is applied to an iontophoresis chamber placed on the skin, which contains a charged active agent and its solvent vehicle. Another chamber or skin electrode carries the return current. One or two chambers are filled with a solution containing the active ingredient and its solvent vehicle. The positively charged chamber, called the anode, repels positively charged species, while the negatively charged chamber, called the cathode, repels negatively charged species into the skin.
[0005] It is known that low voltage iontophoresis devices can safely "move" molecules over 1 cm into tissue beneath the skin, using safe and well-tolerated voltages and currents. Such depths are suitable for the methods disclosed herein, as many injected materials are administered at minimal depths, just beneath the skin or into muscle. Thus, these safe and well-tolerated voltages and currents used in iontophoresis can also be used to control dissipation of material, not by using repulsive forces to move material into the skin, but by using repulsive forces to "fence" or confine material to the desired treatment area. In addition to repulsive forces, attractive forces can also be used to localize the administered material. Summary of the Invention [Problem to be solved by the invention]
[0006] Iontophoresis offers an alternative to injections. However, iontophoresis does not offer the precision of other modes of administration (e.g., needles). Thus, it is an object of the present specification to provide an improved method of administration that utilizes traditional methods of administration, such as injections, in combination with electromagnetic forces, such as electric charges, electric fields, and currents, to control dissipation after administration. In embodiments, charges can be used to attract or repel the administered material. An "attractive" force can be used to increase localization of the injected material, for example, by applying an attractive force to the treatment area, while a "repulsive" force can be used to decrease dissipation of the administered material, for example, by "fencing" the treatment area or aspects thereof with a repulsive force. [Means for solving the problem]
[0007] Embodiments include methods, systems, and devices for localizing or minimizing the diffusion or dissipation of injectable materials (e.g., injectable pharmaceutical compositions).Embodiments include the use of, for example, energy fields, e.g., electromagnetic fields (EMFs), such as electric fields, charges, currents, magnetic fields, or combinations thereof, to localize the injectable compositions.Injectable compositions can include, for example, biologics, neurotoxins, proteins, DNA, viruses, dermal fillers, and the like.
[0008] Embodiments include methods, systems, and devices for increasing the diffusion or dissipation of injectable materials (e.g., injectable pharmaceutical compositions).Embodiments include the use of, for example, energy fields, e.g., electromagnetic fields (EMFs), such as electric fields, charges, currents, magnetic fields, or combinations thereof, to dissipate the injectable compositions.The injectable compositions may include, for example, biologics, neurotoxins, proteins, DNA, viruses, dermal fillers, and the like.
[0009] Embodiments include methods, systems, and devices for directing the diffusion or dissipation of injectable materials (e.g., injectable pharmaceutical compositions).Embodiments include the use of, for example, energy fields, e.g., electromagnetic fields (EMFs), such as electric fields, charges, currents, magnetic fields, or combinations thereof, to localize the injectable compositions.The injectable compositions may include, for example, biologics, neurotoxins, proteins, DNA, viruses, dermal fillers, and the like.
[0010] By localizing the injected material, diffusion or dissipation of the material can be eliminated or reduced, thereby eliminating or reducing the risk of undesirable effects and minimizing the "immunogen footprint" that may result from the injection. By localizing the material, the duration of effect of the injected material, for example, the duration of effect of a neurotoxin injection, or the duration of effect of a dermal filler injection, can be increased. By localizing the material, the intensity of the effect of the injected material, for example, the intensity of the effect of a neurotoxin injection, or the intensity of the effect of a dermal filler injection, can be increased.
[0011] In embodiments, the material is injected subcutaneously, for example to a depth of 1-15 mm, and then an attractive force comprising an electric charge is applied to the injection site. The order of this operation can be reversed, so that the force is applied before or after administration.
[0012] In embodiments, the material is injected subcutaneously, for example to a depth of 1-15 mm, and then a repulsive force comprising an electric charge is applied around or partially around the treatment site. This order of operations can be reversed, so that the force is applied before or after administration.
[0013] In embodiments, the material is injected subcutaneously, for example to a depth of 1-15 mm, then an attractive force comprising a charge is applied to the injection site, and a repulsive force comprising a charge is applied around or partially around the treatment site, the attractive and repulsive forces comprising opposite charges. The order of this operation can be reversed, so that the forces are applied before or after administration. In embodiments, the attractive and repulsive forces establish an electric field. In embodiments where there is electrical conductivity between the attractive and repulsive forces, an electric current can be established.
[0014] Embodiments may include neurotoxin administration to treat, for example, pain, muscle-related conditions, depression, cosmetic concerns, and combinations thereof. For example, to treat pain, muscle-related conditions, depression, cosmetic concerns, etc., an attractant, e.g., TENS device's attractant electrode (determined based on the physical properties of the injected material) can be placed over or near the site of injection of the neurotoxin, and the device's repelling electrode can be placed, for example, 1 inch or less from the attractant electrode. Clinically, TENS is applied with stimulation of various frequencies, intensities, and pulse durations. Using electrodes, the current from the TENS unit is converted into ionic current in the living tissue. During TENS therapy, the pulsed current is generated by either an AC mains power source or a battery (usually 9V) and delivered through the intact skin surface via the electrodes. For methods utilizing TENS, the attractant electrode can be placed over the site of injection material treatment.
[0015] The disclosed embodiments include "active" devices that utilize a power source such as AC or DC power, or pulsed RF or pulsed current, e.g., high voltage pulsed current, or "passive" devices that do not require an external power source. For example, in passive embodiments, electrical energy can be derived from dissimilar metals that generate a battery, e.g., the dissimilar metals are located on a separate dressing or bandage, while those embodiments with an external power source may require conductive electrodes in a spaced configuration to predetermine the shape and strength of the electric field. In active devices, AC or DC current may be used. For example, an exemplary active device suitable for use with the disclosed embodiments includes a TENS device.
[0016] The embodiments disclosed herein include bioelectrical devices that include electrodes. Such matrices can include an electrode formed from a first conductive material, the material including a metal species, and a second electrode formed from a second conductive material, the second conductive material including a metal species that can define at least one voltage cell with the metal species of the first electrode to spontaneously generate at least one electric current when the first electrode and the second electrode connect through an electrolyte, such as an electrolyte in the body, and the first and second electrodes are not in physical contact with each other. Certain embodiments utilize an external power source, such as AC or DC power, or pulsed RF or pulsed current, for example, high voltage pulsed current.
[0017] Further disclosed embodiments may include articles of manufacture that include packaging materials and a quantity of a chemodenervating agent (e.g., a neurotoxin). The chemodenervating agent may be a Clostridial neurotoxin, e.g., a botulinum toxin, such as botulinum toxin A (BoNT / A), botulinum toxin B (BoNT / B), botulinum toxin E (BoNT / E), botulinum toxin F (BoNT / F), combinations thereof, and devices disclosed herein. These articles of manufacture may include, for example, kits that include a neurotoxin or combinations thereof, a disclosed device, and instructions for use.
[0018] The disclosed embodiments include articles of manufacture that include packaging materials, an amount of a cosmetic agent, e.g., a dermal filler, such as hyaluronic acid (HA), and a device disclosed herein. These articles of manufacture can include, for example, kits that include one or more dermal fillers, the disclosed systems and devices, and instructions for use.
[0019] Further embodiments may include a topical agent, such as a cream containing attractive EMFs, for application to the treatment area after treatment. For example, an attractive field generating cream may be applied over the injectable material treatment site (e.g., lip or glabellar areas). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] The present disclosure relates to methods for localizing injectable materials through the use of energy applied to or around an injection site. Such energy can include, for example, electromagnetic energy, such as electrical energy, charge, electric field, magnetic energy, current, combinations thereof, etc.
[0021] For example, BoNT / A has an isoelectric point of approximately 9.2. Thus, at physiological pH values, BoNT / A has a net positive charge. In embodiments, by applying a negative charge source to a location, such as, for example, a desired treatment or injection location, the toxin can be "fixed" to that location or attracted to that location. Similarly, by applying a positive charge source to a location, for example, around some or all of the perimeter of the treatment site, the toxin can be excluded from that location. Type E (BoNT / E) has an isoelectric point of about 6. Thus, at physiological pH values, the toxin has a net negative charge. This electromotive effect of the electric field on the toxin can be seen in SDS / PAGE images.
[0022] Botulinum neurotoxins suitable for use with the disclosed methods and systems include BoNT / A, BoNT / B, BoNT / C, BoNT / D, BoNT / E, BoNT / F, BoNT / G, BoNT / H, and combinations thereof. Additional suitable neurotoxins may include the "light chain" of a botulinum toxin. Embodiments may include combinations of neurotoxins (e.g., BoNT / A and BoNT / E). Embodiments may include dissociation of the heavy and light chains either before or after administration. Disclosed embodiments may include the use of an electric charge, electric field, or current to dissociate the neurotoxin from an accessory protein or formulation component (e.g., HSA) either before or after administration, such as, for example, by injection.
[0023] An embodiment involves aligning the dipoles of the botulinum toxin to provide the correct orientation for binding.
[0024] Similarly, dermal fillers can be localized via the disclosed methods. For example, in embodiments, at physiological pH values, hyaluronic acid has a net negative charge. In embodiments, by applying a positive charge source to a location, the dermal filler can be "fixed" to that location. Similarly, by applying a negative charge source, for example, around some or all of the perimeter of the treatment area, the dermal filler can be excluded or repelled from a location.
[0025] As can be seen from the electrophoretic gel, the migration of the dermal filler can be controlled by the use of an electric field, an electric current, or a combination thereof. Dermal fillers suitable for use with the disclosed methods and systems include, for example, those containing hyaluronic acid (HA), calcium hydroxylapatite (CaHA), poly-L-lactic acid, polymethylmethacrylate (PMMA), autologous fat injections (facial fat grafting), and combinations thereof.
[0026] Embodiments may also include adjusting the pH of the injected material, for example to the isoelectric point of the material, and then applying an electric field to the "surroundings" to localize the material through the use of a repulsive field.
[0027] In embodiments, the electric field can be provided by a substrate, e.g., a flexible substrate, including electrodes of appropriate charge. For example, the positive electrode can include silver. The negative electrode can include zinc. The embodiments include self-contained localized devices that do not require a power source. The embodiments include devices that require a power source, e.g., a power source connected to electrodes such that one or more electrodes generate a negative electric field and one or more electrodes generate a positive electric field. Substrates suitable for use with the disclosed embodiments can include resorbable materials. Substrates suitable for use with the disclosed embodiments can include transparent or opaque materials.
[0028] Disclosed embodiments include the use of magnetic fields to localize injectable materials based on the electrical or magnetic properties of the material. For example, magnetic fields can be used to influence and manipulate the dipoles of molecules (e.g., neurotoxin molecules such as BoNT / A) to orient the molecules into positions that increase or decrease the binding efficiency of the molecules.
[0029] Embodiments include modified neurotoxins, including modifications that increase the inherent "charge" of the molecule or the electrical conductivity of the formulation to increase the effect of the disclosed embodiments.
[0030] definition "Administration" or "administering" refers to the step of giving (i.e., administering) to a subject a pharmaceutical composition or an active ingredient or an injectable material, such as a dermal filler. The materials disclosed herein can be administered via a number of suitable routes, but as described in the disclosed methods, in embodiments, the compositions are administered locally, for example, by intramuscular, intradermal, or subcutaneous routes of administration, for example, by injection or use of an implant.
[0031] By "attractive electromagnetic field" is meant a charge, electric field, or current, eg, an electric field and / or charge, that attracts injectable material.
[0032] "Botulinum toxin" or "botulinum neurotoxin" refers to wild-type neurotoxin derived from Clostridium botulinum, as well as modified, recombinant, hybrid and chimeric botulinum toxins. Recombinant botulinum toxins may have their light and / or heavy chains recombinantly produced by non-clostridial species. "Botulinum toxin" as used herein includes botulinum toxin serotypes A, B, C, D, E, F, G and H. "Botulinum toxin" as used herein also includes both botulinum toxin complexes (i.e., 300, 600 and 900 kDa complexes) and pure botulinum toxins (i.e., approximately 150 kDa neurotoxin molecules), all of which are useful in the practice of the present invention. "Purified botulinum toxin" means a pure botulinum toxin or botulinum toxin complex that is isolated or substantially isolated from other proteins and impurities that may accompany the botulinum toxin when obtained from a culture or fermentation process. Thus, a purified botulinum toxin can be free of at least 95%, more preferably at least 99%, of non-botulinum toxin proteins and impurities.
[0033] "Clostridial neurotoxin" means a neurotoxin produced by or native to a Clostridial bacterium, such as Clostridium botulinum, Clostridium butyricum, or Clostridium beratti, as well as a Clostridial neurotoxin recombinantly produced by a non-Clostridial species.
[0034] "Dermal filler" refers to a composition used in cosmetic treatments that is injected into or under the skin. Typically, they are designed to effectively reduce the appearance of undesirable wrinkles, contour, create volume, and revitalize the skin. Suitable fillers include hyaluronic acid, polyalkylimide, polylactic acid, polymethylmethacrylate microparticles (PMMA), and the like.
[0035] By "limiting" the dissipation of an administered material, it is meant that the total area affected by the administered material is less than the total area that would be affected in the absence of the limiting effect.
[0036] As used herein, "intermediate acting" refers to a botulinum toxin that produces an effect more slowly than a fast-acting toxin.
[0037] "Neurotoxin" means a biologically active molecule that has specific affinity for a neuronal cell surface receptor. Neurotoxins include clostridial toxins both as pure toxins and complexed with one or more non-toxin, toxin-associated proteins.
[0038] "Patient" means a human or non-human subject receiving medical or veterinary care.
[0039] "Pharmaceutical composition" refers to a formulation in which the active ingredient may be a neurotoxin, a dermal filler, etc. The term "formulation" refers to the presence in the pharmaceutical composition of at least one additional ingredient (e.g., but not limited to, albumin [e.g., human serum albumin or recombinant human albumin] and / or sodium chloride) in addition to the botulinum neurotoxin active ingredient. Thus, a pharmaceutical composition is a formulation suitable for diagnostic, therapeutic or cosmetic administration to a subject, such as a human patient. The pharmaceutical composition may be in a lyophilized or vacuum-dried state, e.g., a solution formed after reconstitution of the lyophilized or vacuum-dried pharmaceutical composition with saline or water, or as a solution that does not require reconstitution. As described, the pharmaceutical composition may be liquid or solid. The pharmaceutical composition may be free of animal protein.
[0040] By "repulsive electromagnetic field" is meant a charge, electric field, or current, eg, a magnetic field or electric field or charge, that repels the injected material.
[0041] By "substantially free" is meant that the weight percent of the substance is present at a level of less than 1 weight percent of the culture medium, fermentation medium, pharmaceutical composition or other material being evaluated.
[0042] "Therapeutic formulation" means a formulation that can be used to treat and thereby alleviate a disorder or disease and / or symptoms associated therewith, e.g., a disorder or disease characterized by peripheral muscle activity.
[0043] "Therapeutically effective amount" means the level, amount, or concentration of an agent (e.g., a botulinum toxin, or a pharmaceutical composition containing a botulinum toxin) required to treat a disease, disorder, or condition without causing significant negative or adverse side effects.
[0044] By "toxin naive" is meant a patient who has never been administered a neurotoxin, such as a Clostridial toxin (eg, BoNT / A).
[0045] "Treate," "treating," or "treatment" means the alleviation or reduction (including some reduction, significant reduction, near complete reduction, and complete reduction), resolution or prevention (either temporarily or permanently) of a disease, disorder or condition to achieve a desired therapeutic or cosmetic result, for example, by healing injured or damaged tissue or by altering, modifying, enhancing, improving, ameliorating, and / or beautifying an existing or perceived disease, disorder or condition.
[0046] By "unit" or "U" is meant an amount of active BoNT standardized to have an equivalent neuromuscular blocking effect as a unit of commercially available BoNT / A.
[0047] Treatment methods In embodiments, the method of localizing the injected material may include applying an energy field, such as a charge, an electric field, or a current, or a combination thereof, to at least one injection site, or applying an energy field, such as a charge, an electric field, or a current, or a combination thereof, to the periphery of at least one injection site, and combinations thereof.For example, an energy field, such as an attractive charge, an electric field, or a current, or a combination thereof, may be applied directly to the top of the injection site.In embodiments, an energy field, such as a repulsive charge, an electric field, or a current, or a combination thereof, may be applied around the periphery of one or more injection sites.These methods may be combined so that attractive and repulsive forces are applied.
[0048] In embodiments, the method of minimizing the immune response caused by the injection material can include applying an energy field, such as a charge, an electric field, or a current, or a combination thereof, to at least one injection site or around at least one injection site.For example, an attractive energy field, such as a charge, an electric field, or a current, or a combination thereof, can be applied directly to the top of the injection site.In embodiments, a repulsive energy field, such as a charge, an electric field, or a current, or a combination thereof, can be applied around one or more injection sites or around a part of the surroundings.These methods can be combined to apply an attractive field and a repulsive field.
[0049] In embodiments, the energy field may include, for example, an electric field, an electric charge, a current, a magnetic field, a combination thereof, and the like. For example, an electric field can be applied to the injection site by using electrodes that provide a suitable voltage to generate an attractive field to "attract" the substance. In embodiments, an electric field can be applied to surround (partially or completely) the injection site by using electrodes that provide a suitable voltage to generate a repulsive field to "repel" the substance. In embodiments, both attractive and repulsive fields are applied. In this manner, the diffusion or dissipation of the injected material can be reduced or eliminated.
[0050] In embodiments, the electric field can include a voltage suitable for application to a mammal. For example, a suitable electric field can include a voltage suitable for application to the body of a mammal (e.g., a human).
[0051] In various embodiments, the difference in standard potential of the electrodes providing the attractive and repulsive fields can range from about 0.05 V to approximately about 10.0 V. For example, the standard potential can be about 0.05 V, about 0.06 V, about 0.07 V, about 0.08 V, about 0.09 V, about 0.1 V, about 0.2 V, about 0.3 V, about 0.4 V, about 0.5 V, about 0.6 V, about 0.7 V, about 0.8 V, about 0.9 V, about 1.0 V, about 1.1 V, about 1.2 V, about 1.3 V, about 1.4 V, about 1.5 V, about 1.6 V, about 1.7 V, about 1.8 V, about 1.9 V, about 2.0 V, about 2.1 V, about 2.2 V, about 2.3 V, about 2.4 V, about 2.5 V, about 2.6 V, about 2.7 V, about 2.8 V, about 2.9 V, about 2.8 V, about 2.9 V, about 2.9 V, about 2.8 V, about 2.9 V, about 2.9 V, about 2.0 V, about 2.1 V, about 2.2 V, about 2.4 V, about 2.5 V, about 2.6 V, about 2.7 V, about 2.8 V, about 2.9 ... .8V, approximately 1.9V, approximately 2.0V, approximately 2.1V, approximately 2.2V, approximately 2.3V, approximately 2.4V, approximately 2.5V, approximately 2.6V, approximately 2.7V, approximately 2.8V, approximately 2.9V, approximately 3.0V , about 3.1V, about 3.2V, about 3.3V, about 3.4V, about 3.5V, about 3.6V, about 3.7V, about 3.8V, about 3.9V, about 4.0V, about 4.1V, about 4.2V, about 4 .3V, approx. 4.4V, approx. 4.5V, approx. 4.6V, approx. 4.7V, approx. 4.8V, approx. 4.9V, approx. 5.0V, approx. 5.1V, approx. 5.2V, approx. 5.3V, approx. 5.4V, approx. 5.5V , about 5.6V, about 5.7V, about 5.8V, about 5.9V, about 6.0V, about 6.1V, about 6.2V, about 6.3V, about 6.4V, about 6.5V, about 6.6V, about 6.7V, about 6 .8V, approximately 6.9V, approximately 7.0V, approximately 7.1V, approximately 7.2V, approximately 7.3V, approximately 7.4V, approximately 7.5V, approximately 7.6V, approximately 7.7V, approximately 7.8V, approximately 7.9V, approximately 8.0V , about 8.1V, about 8.2V, about 8.3V, about 8.4V, about 8.5V, about 8.6V, about 8.7V, about 8.8V, about 8.9V, about 9.0V, about 10.0V, etc.
[0052] In embodiments, the electric field between the attracting and repelling electrodes can be, for example, 20 volts / cm, 19 volts / cm, 18 volts / cm, 17 volts / cm, 16 volts / cm, 15 volts / cm, 14 volts / cm, 13 volts / cm, 12 volts / cm, 11 volts / cm, 10 volts / cm, 9 volts / cm, 8 volts / cm, 7 volts / cm, 6 volts / cm, 5 volts / cm, 4 volts / cm, 3 volts / cm, 2 volts / cm, 1 volt / cm, etc.
[0053] In embodiments, the electric field between the attracting electrode and the repelling electrode can be, for example, 20 volts / cm to 1 v / cm, 19 volts / cm to 2 v / cm, 18 volts / cm to 3 v / cm, 17 volts / cm to 4 v / cm, 16 volts / cm to 5 v / cm, 15 volts / cm to 6 v / cm, 14 volts / cm to 7 v / cm, 13 volts / cm to 8 v / cm, 12 volts / cm to 9 v / cm, 11 volts / cm to 10 v / cm, etc.
[0054] In embodiments, the electric field between the attracting electrode and the repelling electrode can be, for example, 20 volts / cm or less, 19 volts / cm or less, 18 volts / cm or less, 17 volts / cm or less, 16 volts / cm or less, 15 volts / cm or less, 14 volts / cm or less, 13 volts / cm or less, 12 volts / cm or less, 11 volts / cm or less, 10 volts / cm or less, 9 volts / cm or less, 8 volts / cm or less, 7 volts / cm or less, 6 volts / cm or less, 5 volts / cm or less, 4 volts / cm or less, 3 volts / cm or less, 2 volts / cm or less, 1 volt / cm or less, etc.
[0055] In embodiments, the electric field between the attracting electrode and the repelling electrode can be, for example, 20 volts / cm or more, 19 volts / cm or more, 18 volts / cm or more, 17 volts / cm or more, 16 volts / cm or more, 15 volts / cm or more, 14 volts / cm or more, 13 volts / cm or more, 12 volts / cm or more, 11 volts / cm or more, 10 volts / cm or more, 9 volts / cm or more, 8 volts / cm or more, 7 volts / cm or more, 6 volts / cm or more, 5 volts / cm or more, 4 volts / cm or more, 3 volts / cm or more, 2 volts / cm or more, 1 volt / cm or more, etc.
[0056] Embodiments may include current between the attracting electrode and the repelling electrode. In embodiments, the systems and devices disclosed herein may be configured to deliver current at, for example, about 1 to about 200 microamps, about 10 to about 190 microamps, about 20 to about 180 microamps, about 30 to about 170 microamps, about 40 to about 160 microamps, about 50 to about 150 microamps, about 60 to about 140 microamps, about 70 to about 130 microamps, about 80 to about 120 microamps, about 90 to about 100 microamps, about 100 to about 150 microamps, about 150 to about 200 microamps, about 20 0 to 250 microamperes, 250 to 300 microamperes, 300 to 350 microamperes, 350 to 400 microamperes, 400 to 450 microamperes, 450 to 500 microamperes, 500 to 550 microamperes, 550 to 600 microamperes, 600 to 650 microamperes, 650 to 700 microamperes, 700 to 750 microamperes, 750 to 800 microamperes, 800 to 850 microamperes, 850 to 900 microamperes 900 to 950 microamperes, 950 to 1000 microamperes (1 milliampere [mA]), 1.0 to 1.1 mA, 1.1 to 1.2 mA, 1.2 to 1.3 mA, 1.3 to 1.4 mA, 1.4 to 1.5 mA, 1.5 to 1.6 mA, 1.6 to 1.7 mA, 1.7 to 1.8 mA, 1.8 to 1.9 mA, 1.9 to 2.0 mA, 2.0 to 2.1 mA, 2.1 to 2.2 mA, 2.2 to 2.3 mA, 2.3 to 2.4 mA, 2.4 to 2.5 mA, 2.5 to About 2.6mA, about 2.6 to about 2.7mA, about 2.7 to about 2.8mA, about 2.8 to about 2.9mA, about 2.9 to about 3.0mA, about 3.0 to about 3.1mA, about 3.1 to about 3.2mA, about 3.2 to about 3.3mA, about 3.3 to about 3.4mA, about 3.4 to about 3.5mA, about 3.5 to about 3.6mA, about 3.6 to about 3.7mA, about 3.7 to about 3.8mA, about 3.8 to about 3.9mA, about 3.9 to about 4.0mA, about 4.0 to about 4.1mA, about 4.1 to about 4.2mA, about 4.2 to about 4.3mA, about 4.3 to about 4.4mA, about 4.4 to about 4.5mA, about 4.5 to about 5.0mA, about 5.0 to about 5.5mA, about 5.5 to about 6.0mA, about 6.0 to about 6.5mA, about 6.5 to about 7.0mA, about 7.5 to about 8.0mA, about 8.0 to about 8.5mA, about 8.5 to about 9.0mA, about 9.0 to about 9.5mA, about 9.5 to about 10.0mA, about 10.0 to about 10.5mA, about 10.5 to about 11.0mA, A low level of current between the attracting electrode and the repelling electrode may be generated, such as about 11.0 to about 11.5 mA, about 11.5 to about 12.0 mA, about 12.0 to about 12.5 mA, about 12.5 to about 13.0 mA, about 13.0 to about 13.5 mA, about 13.5 to about 14.0 mA, about 14.0 to about 14.5 mA, or about 14.5 to about 15.0 mA.
[0057] In embodiments, the systems and devices disclosed herein may generate low levels of current, such as, for example, from about 1 microamp to about 1 milliamp, from about 50 to about 800 microamps, from about 200 to about 600 microamps, or from about 400 to about 500 microamps.
[0058] In embodiments, the systems and devices disclosed herein provide a current limiting capability of about 10 microamps, about 20 microamps, about 30 microamps, about 40 microamps, about 50 microamps, about 60 microamps, about 70 microamps, about 80 microamps, about 90 microamps, about 100 microamps, about 110 microamps, about 120 microamps, about 130 microamps, about 140 microamps, about 150 microamps, about 160 microamps, about 170 microamps, about 180 microamps, about 190 microamps, about 200 microamps, about 210 microamps, about 220 microamps, about 230 microamps, about 240 microamps, about 250 microamps, about 260 microamps, about 270 microamps, about 280 microamps, about 290 microamps, about 300 microamps, about 310 microamps, about 320 microamps, about 330 microamps, about 340 microamps, about 350 microamps, about 360 microamps, about 370 microamps, about 380 microamps, about 390 microamps, about 400 microamps, about 410 microamps, about 420 microamps, about 430 microamps, about 440 microamps, about 450 microamps, about 460 microamps, about 470 microamps, about 480 microamps, about 490 microamps, about 500 microamps, about 510 microamps, about 520 microamps, about 530 microamps, about 540 microamps, about 550 microamps, about 560 microamps, 100 microamperes, 190 microamperes, 200 microamperes, 210 microamperes, 220 microamperes, 240 microamperes, 260 microamperes, 280 microamperes, 300 microamperes, 320 microamperes, 340 microamperes, 360 microamperes, 380 microamperes, 400 microamperes, 450 microamperes, 500 microamperes, 550 microamperes, 600 microamperes, 650 microamperes, 700 microamperes amperes, 750 microamperes, 800 microamperes, 850 microamperes, 900 microamperes, 950 microamperes, 1 milliampere (mA), 1.1 mA, 1.2 mA, 1.3 mA, 1.4 mA, 1.5 mA, 1.6 mA, 1.7 mA, 1.8 mA, 1.9 mA, 2.0 mA, 2.1 mA, 2.2 mA, 2.3 mA, 2.4 mA, 2.5 mA, 2.6 mA, 2.7 mA, 2.8 mA, 2.9 mA, 3.0 mA, 3.1 mA, 3.2 mA, 3.3 mA, 3.4 mA , approx. 3.5mA, approx. 3.6mA, approx. 3.7mA, approx. 3.8mA, approx. 3.9mA, approx. 4.0mA, approx. 4.1mA, approx. 4.2mA, approx. 4.3m A, approx. 4.4mA, approx. 4.5mA, approx. 4.6mA, approx. 4.7mA, approx. 4.8mA, approx. 4.9mA, approx. 5.0mA, approx. 5.1mA, approx. 5.2 mA, approx. 5.3mA, approx. 5.4mA, approx. 5.5mA, approx. 5.6mA, approx. 5.7mA, approx. 5.8mA, approx. 5.9mA, approx. 6.0mA, approx. 6. 1mA, approx. 4.2mA, approx. 6.3mA, approx. 6.4mA, approx. 6.5mA, approx. 6.6mA, approx. 6.7mA, approx. 6.8mA, approx. 6.9mA, approx. 7.0mA, approximately 7.1mA, approximately 7.2mA, approximately 7.3mA, approximately 7.4mA, approximately 7.5mA, approximately 7.6mA, approximately 7.7mA, approximately 7.8mA, approximately 7.9mA, approximately 8.0mA, approximately 8.1mA, approximately 8.2m A, approximately 8.3mA, approximately 8.4mA, approximately 8.5mA, approximately 8.6mA, approximately 8.7mA, approximately 8.8mA, approximately 8.9mA, approximately 9.0mA, approximately 9.1mA, approximately 9.2mA, approximately 9.3mA, approximately 9.4mA, approximately 9.5mA, approximately 9.6mA, approximately 9.7mA, approximately 9.8mA, approximately 9.9mA, approximately 10.0mA, approximately 10.1mA, approximately 10.2mA, approximately 10.3mA, approximately 10.4mA, approximately 10.5mA, approximately 10.6 mA, approximately 10.7mA, approximately 10.8mA, approximately 10.9mA, approximately 11.0mA, approximately 11.1mA, approximately 11.2mA, approximately 11.3mA, approximately 11.4mA, approximately 11.5mA, approximately 11.6mA, approximately 11. 7mA, approximately 11.8mA, approximately 11.9mA, approximately 12.0mA, approximately 12.1mA, approximately 12.2mA, approximately 12.3mA, approximately 12.4mA, approximately 12.5mA, approximately 12.6mA, approximately 12.7mA, approximately 12 .8mA, approx. 12.9mA, approx. 13.0mA, approx. 13.1mA, approx. 13.2mA, approx. 13.3mA, approx. 13.4mA, approx. 13.5mA, approx. 13.6mA, approx. 13.7mA, approx. 13.8mA, approx. 1 It may generate low levels of current such as about 3.9 mA, about 14.0 mA, about 14.1 mA, about 14.2 mA, about 14.3 mA, about 14.4 mA, about 14.5 mA, about 14.6 mA, about 14.7 mA, about 14.8 mA, about 14.9 mA, about 15.0 mA, about 15.1 mA, about 15.2 mA, about 15.3 mA, about 15.4 mA, about 15.5 mA, about 15.6 mA, about 15.7 mA, about 15.8 mA, etc.
[0059] In embodiments, the disclosed systems and devices provide current dissipation of 10 microamps or less, or about 20 microamps or less, about 30 microamps or less, about 40 microamps or less, about 50 microamps or less, about 60 microamps or less, about 70 microamps or less, about 80 microamps or less, about 90 microamps or less, about 100 microamps or less, about 110 microamps or less, about 120 microamps or less, about 130 microamps or less, about 140 microamps or less, about 150 microamps or less, about 160 microamps or less, about 170 microamps or less, about 180 microamps or less, about 190 microamps or less, about 200 microamps or less, about 210 microamps or less, about 220 microamps or less, about 230 microamps or less, about 240 microamps or less, about 250 microamps or less, about 260 microamps or less, about 270 microamps or less, about 280 microamps or less, about 290 microamps or less, about 300 microamps or less, about 310 microamps or less, about 320 microamps or less, about 330 microamps or less, about 340 microamps or less, about 350 microamps or less, about 360 microamps or less, about 370 microamps or less, about 380 microamps or less, about 390 microamps or less, about 400 microamps or less, about 410 microamps or less, about 420 microamps or less, about 430 microamps or less, about 440 microamps or less, about 450 microamps or less, about 460 microamps or less microamperes or less, about 170 microamperes or less, about 180 microamperes or less, about 190 microamperes or less, about 200 microamperes or less, about 210 microamperes or less, about 220 microamperes or less, about 230 microamperes or less, about 240 microamperes or less, about 250 microamperes or less, about 260 microamperes or less, about 270 microamperes or less, about 280 microamperes or less, about 290 microamperes or less, about 300 microamperes or less, about 310 microamperes or less, about 320 microamperes or less below, about 340 microamperes or less, about 360 microamperes or less, about 380 microamperes or less, about 400 microamperes or less, about 420 microamperes or less, about 440 microamperes or less, about 460 microamperes or less, about 480 microamperes or less, about 500 microamperes or less, about 520 microamperes or less, about 540 microamperes or less, about 560 microamperes or less, about 580 microamperes or less, about 600 microamperes or less, about 620 microamperes or less, about 640 microamperes or less, about 660 microamperes or less microamperes or less, about 680 microamperes or less, about 700 microamperes or less, about 720 microamperes or less, about 740 microamperes or less, about 760 microamperes or less, about 780 microamperes or less, about 800 microamperes or less, about 820 microamperes or less, about 840 microamperes or less, about 860 microamperes or less, about 880 microamperes or less, about 900 microamperes or less, about 920 microamperes or less, about 940 microamperes or less, about 960 microamperes or less, about 980 microamperes or less,About 1 milliamp (mA) or less, about 1.1 mA or less, about 1.2 mA or less, about 1.3 mA or less, about 1.4 mA or less, about 1.5 mA or less, about 1.6 mA or less, about 1.7 mA or less, about 1.8 mA or less, about 1.9 mA or less, about 2.0 mA or less, about 2.1 mA or less, about 2.2 mA or less, about 2.3 mA or less, about 2.4 mA or less, about 2.5 mA or less, about 2.6 mA or less, about 2.7 mA or less, about 2.8 mA or less, about 2.9 mA or less, about 3.0 mA or less, about 3.1 mA or less, about 3.2 mA or less, about 3.3 mA or less, about 3.4 mA or less, about 3.5 mA or less, about 3.6 mA or less , about 3.7mA or less, about 3.8mA or less, about 3.9mA or less, about 4.0mA or less, about 4.1mA or less, about 4.2mA or less, about 4.3mA or less, about 4.4mA or less, about 4.5mA or less, about 4.6mA or less, about 4.7mA or less, about 4.8mA or less, about 4.9mA or less, about 5.0mA or less, about 5.1mA or less, about 5.2mA or less, about 5.3mA or less, about 5.4mA or less, about 5.5mA or less, about 5.6mA or less, about 5.7mA or less, about 5.8mA or less, about 5.9mA or less, about 6.0mA or less, about 6.1mA or less, about 4.2mA or less, about 6.3mA or less, about 6.4mA or less A or less, about 6.5mA or less, about 6.6mA or less, about 6.7mA or less, about 6.8mA or less, about 6.9mA or less, about 7.0mA or less, about 7.1mA or less, about 7.2mA or less, about 7.3mA or less, about 7.4mA or less, about 7.5mA or less, about 7.6mA or less, about 7.7mA or less, about 7.8mA or less, about 7.9mA or less, about 8.0mA or less, about 8.1mA or less, about 8.2mA or less, about 8.3mA or less, about 8.4mA or less, about 8.5mA or less, about 8.6mA or less, about 8.7mA or less, about 8.8mA or less, about 8.9mA or less, about 9.0mA or less, about 9.1mA or less, about 9.2mA or less, about 9.3mA or less, about 9.4mA or less, about 9.5mA or less, about 9.6mA or less, about 9.7mA or less, about 9.8mA or less, about 9.9mA or less, about 10.0mA or less, about 10.1mA or less, about 10.2mA or less, about 10.3mA or less, about 10.4mA or less, about 10.5mA or less, about 10.6mA or less, about 10.7mA or less, about 10.8mA or less, about 10.9mA or less, about 1.0mA or less, about 11.1mA or less, about 1.2mA or less, about 11.3mA or less, about 11.4mA or less, about 11.5mA or less, about 11.6mA or less, about 11.7mA or less,Approximately 11.8mA or less, approximately 11.9mA or less, approximately 12.0mA or less, approximately 12.1mA or less, approximately 12.2mA or less, approximately 12.3mA or less, approximately 12.4mA or less, approximately 12.5mA or less, approximately 12.6mA or less, approximately 2.7mA or less, approximately 12.8mA Below, about 12.9mA or less, about 13.0mA or less, about 13.1mA or less, about 13.2mA or less, about 13.3mA or less, about 13.4mA or less, about 13.5mA or less, about 13.6mA or less, about 13.7mA or less, about 13.8mA or less, about 13 The device may generate low levels of current, such as about 0.9 mA or less, about 14.0 mA or less, about 14.1 mA or less, about 14.2 mA or less, about 14.3 mA or less, about 14.4 mA or less, about 14.5 mA or less, about 14.6 mA or less, about 14.7 mA or less, about 14.8 mA or less, about 14.9 mA or less, about 15.0 mA or less, about 15.1 mA or less, about 15.2 mA or less, about 15.3 mA or less, about 15.4 mA or less, about 15.5 mA or less, about 15.6 mA or less, about 15.7 mA or less, about 15.8 mA or less, etc.
[0060] In embodiments, the systems and devices disclosed herein provide a pulse width of about 11.8 mA or more, about 11.9 mA or more, about 12.0 mA or more, about 12.1 mA or more, about 12.2 mA or more, about 12.3 mA or more, about 12.4 mA or more, about 12.5 mA or more, about 12.6 mA or more, about 12.7 mA or more, about 12.8 mA or more, about 12.9 mA or more, about 13.0 mA or more, about 13.1 mA or more, about 13.2 mA or more, about 13.3 mA or more, about 13.4 mA or more, about 13.5 mA or more, about 13.6 mA or more, about 13.7 mA or more or low levels of current such as about 13.8 mA or more, about 13.9 mA or more, about 14.0 mA or more, about 14.1 mA or more, about 14.2 mA or more, about 14.3 mA or more, about 14.4 mA or more, about 14.5 mA or more, about 14.6 mA or more, about 14.7 mA or more, about 14.8 mA or more, about 14.9 mA or more, about 15.0 mA or more, about 15.1 mA or more, about 15.2 mA or more, about 15.3 mA or more, about 15.4 mA or more, about 15.5 mA or more, about 15.6 mA or more, about 15.7 mA or more, or about 15.8 mA or more.
[0061] In embodiments, the disclosed devices are capable of providing electric fields of greater than physiological strength to a depth (measured from the device surface) of at least 1 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, 25 mm, 26 mm, 27 mm, 28 mm, 29 mm, 30 mm, 31 mm, 32 mm, 33 mm, 34 mm, 35 mm, 36 mm, 37 mm, 38 mm, 39 mm, 40 mm, or greater.
[0062] In embodiments, the disclosed devices are capable of providing electric fields of greater than physiological strengths to depths (measured from the device surface) of 1 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, 25 mm, 26 mm, 27 mm, 28 mm, 29 mm, 30 mm, 31 mm, 32 mm, 33 mm, 34 mm, 35 mm, 36 mm, 37 mm, 38 mm, 39 mm, 40 mm or less, or greater.
[0063] In active embodiments (e.g., utilizing a TENS device), TENS is applied at a high frequency (above 50 Hz) at an intensity lower than motor contractions (sensory intensity) or at a low frequency (below 10 Hz) at an intensity that produces motor contractions. The disclosed embodiments typically utilize an intensity lower than that required to produce a motor contraction. In an embodiment, an attractant electrode is placed over the treatment area.
[0064] In embodiments, the charge, electric field, current, or combination thereof is applied using a system that includes a device that includes an electrode.For example, the disclosed device can include a conductive electrode.In embodiments, the device includes an attracting electrode and a repelling electrode, and the attracting electrode and the repelling electrode include opposite charges.For example, in a device that uses electric power, the electrode can include platinum, and one of the attracting / repelling electrodes includes a positive charge and the other includes a negative charge.
[0065] The disclosed embodiments can be used to limit the amount of non-therapeutic material injected into a patient. For example, in embodiments, a container containing the material to be injected is subjected to an electromagnetic field that attracts the therapeutic material, and the injected material is drawn from the container into the vicinity of the attracting electromagnetic field.
[0066] injection material In embodiments, the injectable material may include a pharmaceutical composition. For example, a suitable pharmaceutical composition may include any material that is typically administered via injection (including needleless injection). Such a composition may include a neurotoxin, such as a botulinum toxin.
[0067] For example, in the disclosed embodiments, the neurotoxin is formulated in a unit dosage form. For example, it may be provided as a sterile solution in a vial containing a lyophilized powder for reconstitution with a suitable vehicle, such as saline for injection, or as a vial or sachet. Although examples of administration routes and dosages are provided, the appropriate administration route and dosage are generally determined on a case-by-case basis by the attending physician. Such determinations are routine for those skilled in the art. For example, the administration route and administration dosage of the Clostridial neurotoxin according to the present disclosure can be selected based on criteria such as the solubility characteristics of the neurotoxin chosen, and the intensity and extent of the condition being treated.
[0068] The neurotoxin is approximately 10 ”3 In embodiments, the neurotoxin may be administered in an amount of about 10 U / kg to about 35 U / kg. ”2 In another embodiment, the neurotoxin is administered in an amount of about 10 U / kg to about 25 U / kg._1 In another embodiment, the neurotoxin is administered in an amount of about 1 U / kg to about 15 U / kg. In another embodiment, the neurotoxin is administered in an amount of about 1 U / kg to about 10 U / kg. In many cases, administration of about 1 unit to about 500 units of a neurotoxin, such as botulinum type E, provides effective therapeutic relief. In an embodiment, about 5 units to about 200 units of a neurotoxin (e.g., botulinum type E) can be used, and in another embodiment, about 10 units to about 100 units of a neurotoxin (e.g., botulinum type E) can be administered locally to a target tissue, such as muscle.
[0069] In embodiments, administration is about 10 units of neurotoxin, or about 20 units of neurotoxin, or about 30 units of neurotoxin, or about 40 units of neurotoxin, or about 50 units of neurotoxin, or about 60 units of neurotoxin, or about 70 units of neurotoxin, or about 80 units of neurotoxin, or about 90 units of neurotoxin, or about 100 units of neurotoxin, or about 110 units of neurotoxin, or about 120 units of neurotoxin, or about 130 units of neurotoxin. or about 140 units of neurotoxin, or about 150 units of neurotoxin, or about 160 units of neurotoxin, or about 170 units of neurotoxin, or about 180 units of neurotoxin, or about 190 units of neurotoxin, or about 200 units of neurotoxin, or about 210 units of neurotoxin, or about 220 units of neurotoxin, or about 230 units of neurotoxin, or about 240 units of neurotoxin, or about 250 units of neurotoxin, or about 260 units of neurotoxin. or about 270 units of neurotoxin, or about 280 units of neurotoxin, or about 290 units of neurotoxin, or about 290 units of neurotoxin, or about 300 units of neurotoxin, or about 310 units of neurotoxin, or about 320 units of neurotoxin, or about 330 units of neurotoxin, or about 340 units of neurotoxin, or about 350 units of neurotoxin, or about 360 units of neurotoxin, or about 370 units of neurotoxin, or about 380 units of neurotoxin The dose may include about 390 units of neurotoxin, or about 400 units of neurotoxin, or about 410 units of neurotoxin, or about 420 units of neurotoxin, or about 430 units of neurotoxin, or about 440 units of neurotoxin, or about 450 units of neurotoxin, or about 460 units of neurotoxin, or about 470 units of neurotoxin, or about 480 units of neurotoxin, or about 490 units of neurotoxin, or about 500 units of neurotoxin.
[0070] In embodiments, administration is of 10 or more units of a neurotoxin, 20 or more units of a neurotoxin, 30 or more units of a neurotoxin, 40 or more units of a neurotoxin, 50 or more units of a neurotoxin, 60 or more units of a neurotoxin, 70 or more units of a neurotoxin, 80 or more units of a neurotoxin, 90 or more units of a neurotoxin, 100 or more units of a neurotoxin, 110 or more units of a neurotoxin, 120 or more units of a neurotoxin, 130 or more units of a neurotoxin, 140 or more units of a neurotoxin, 150 or more units of a neurotoxin, 160 or more units of a neurotoxin, or about 170 or more units of a neurotoxin, or about 180 units of a neurotoxin, 190 or more units of a neurotoxin, 200 or more units of a neurotoxin, 210 or more units of a neurotoxin, 220 or more units of a neurotoxin, 230 or more units of a neurotoxin, 240 or more units of a neurotoxin, 250 or more units of a neurotoxin, 260 or more units of a neurotoxin, The dose may include a dose of a neurotoxin, 270 or more units of a neurotoxin, 280 or more units of a neurotoxin, 290 or more units of a neurotoxin, or about 290 units of a neurotoxin, 300 or more units of a neurotoxin, 310 or more units of a neurotoxin, 320 or more units of a neurotoxin, 330 or more units of a neurotoxin, 340 or more units of a neurotoxin, 350 or more units of a neurotoxin, 360 or more units of a neurotoxin, 370 or more units of a neurotoxin, 380 or more units of a neurotoxin, 390 or more units of a neurotoxin, 400 or more units of a neurotoxin, 410 or more units of a neurotoxin, 420 or more units of a neurotoxin, 430 or more units of a neurotoxin, 440 or more units of a neurotoxin, 450 or more units of a neurotoxin, 460 or more units of a neurotoxin, 470 or more units of a neurotoxin, 480 or more units of a neurotoxin, 490 or more units of a neurotoxin, 500 or more units of a neurotoxin, etc.
[0071] In embodiments, administration is of 10 units or less of neurotoxin, 20 units or less of neurotoxin, 30 units or less of neurotoxin, 40 units or less of neurotoxin, 50 units or less of neurotoxin, 60 units or less of neurotoxin, 70 units or less of neurotoxin, 80 units or less of neurotoxin, 90 units or less of neurotoxin, 100 units or less of neurotoxin, 110 units or less of neurotoxin, 120 units or less of neurotoxin, 130 units or less of neurotoxin, 140 units or less of neurotoxin, 150 units or less of neurotoxin, 160 units or less of neurotoxin, 170 units or less of neurotoxin, 180 units or less of neurotoxin, 190 units or less of neurotoxin, 200 units or less of neurotoxin, 210 units or less of neurotoxin, 220 units or less of neurotoxin, 230 units or less of neurotoxin, 240 units or less of neurotoxin, 250 units or less of neurotoxin, 260 units or less of neurotoxin, 270 units or less of neurotoxin, 280 units or less of neurotoxin, 290 units or less of neurotoxin, 300 units or less of neurotoxin, 310 units or less of neurotoxin, 320 units or less of neurotoxin, 330 units or less of neurotoxin, 340 units or less of neurotoxin, 350 units or less of neurotoxin, 360 units or less of neurotoxin, 370 units or less of neurotoxin, 380 units or less of neurotoxin, 390 units or less of neurotoxin, 400 units or less The dosage may include up to 500 units of neurotoxin, 270 units of neurotoxin or less, 280 units of neurotoxin or less, 290 units of neurotoxin or less, 300 units of neurotoxin or less, 310 units of neurotoxin or less, 320 units of neurotoxin or less, 330 units of neurotoxin or less, 340 units of neurotoxin or less, 350 units of neurotoxin or less, 360 units of neurotoxin or less, 370 units of neurotoxin or less, 380 units of neurotoxin or less, 390 units of neurotoxin or less, 400 units of neurotoxin or less, 410 units of neurotoxin or less, 420 units of neurotoxin or less, 430 units of neurotoxin or less, 440 units of neurotoxin or less, 450 units of neurotoxin or less, 460 units of neurotoxin or less, 470 units of neurotoxin or less, 480 units of neurotoxin or less, 490 units of neurotoxin or less, 500 units of neurotoxin or less, etc.
[0072] In embodiments, the dose of the neurotoxin is expressed in terms of protein amount or concentration. For example, in embodiments, the neurotoxin may be administered in an amount of about 0.2 ng to 20 ng. In embodiments, the neurotoxin is administered to a target tissue, such as muscle, in an amount of about 0.3 ng to 19 ng, about 0.4 ng to 18 ng, about 0.5 ng to 17 ng, about 0.6 ng to 16 ng, about 0.7 ng to 15 ng, about 0.8 ng to 14 ng, about 0.9 ng to 13 ng, about 1.0 ng to 12 ng, about 1.5 ng to 11 ng, about 2 ng to 10 ng, about 5 ng to 7 ng, etc.
[0073] In embodiments, administration of neurotoxin may include a total dose of 5-7 ng, 7-9 ng, 9-11 ng, 11-13 ng, 13-15 ng, 15-17 ng, 17-19 ng, etc.
[0074] In embodiments, administration may include a total dose of 5 ng or less, 6 ng or less, 7 ng or less, 8 ng or less, 9 ng or less, 10 ng or less, 11 ng or less, 12 ng or less, 13 ng or less, 14 ng or less, 15 ng or less, 16 ng or less, 17 ng or less, 18 ng or less, 19 ng or less, 20 ng or less, etc.
[0075] In embodiments, administration of neurotoxin may include a total dose of 5 ng or more, 6 ng or more, 7 ng or more, 8 ng or more, 9 ng or more, 10 ng or more, 11 ng or more, 12 ng or more, 13 ng or more, 14 ng or more, 15 ng or more, 16 ng or more, 17 ng or more, 18 ng or more, 19 ng or more, 20 ng or more, etc.
[0076] In embodiments, administration is at about 0.1 ng neurotoxin, 0.2 ng neurotoxin, 0.3 ng neurotoxin, 0.4 ng neurotoxin, 0.5 ng neurotoxin, 0.6 ng neurotoxin, 0.7 ng neurotoxin, 0.8 ng neurotoxin, 0.9 ng neurotoxin, 1.0 ng neurotoxin, 1.1 ng neurotoxin, 1.2 ng neurotoxin, 1.3 ng neurotoxin, 1.4 ng neurotoxin, 1.5 ng neurotoxin, 1.6 ng neurotoxin, 1.7 ng neurotoxin, 1.8 ng neurotoxin, 1.9 ng neurotoxin, 2.0 ng neurotoxin, 2.1 ng neurotoxin, 2.2 ng neurotoxin, 2.3 ng neurotoxin, 2.4ng neurotoxin, 2.5ng neurotoxin, 2.6ng neurotoxin, 2.7ng neurotoxin, 2.8ng neurotoxin, 2.9ng neurotoxin, 3.0ng neurotoxin, 3.1ng neurotoxin, 3.2ng neurotoxin, 3.3ng neurotoxin, 3.4ng neurotoxin, 3.5ng neurotoxin, 3.6n neurotoxin, 3.7n neurotoxin, 3.8n neurotoxin, 3.9ng neurotoxin, 4.0ng neurotoxin, 4.1ng neurotoxin, 4.2ng neurotoxin The total dose of the toxin may include 4.3 ng neurotoxin, 4.4 ng neurotoxin, 4.5 ng neurotoxin, 5 ng neurotoxin, 6 ng neurotoxin, 7 ng neurotoxin, 8 ng neurotoxin, 9 ng neurotoxin, 10 ng neurotoxin, 11 ng neurotoxin, 12 ng neurotoxin, 13 ng neurotoxin, 14 ng neurotoxin, 15 ng neurotoxin, 16 ng neurotoxin, 17 ng neurotoxin, 18 ng neurotoxin, 19 ng neurotoxin, 20 ng neurotoxin, and the like.
[0077] In embodiments, administration is at about 0.1 ng neurotoxin, 0.2 ng neurotoxin, 0.3 ng neurotoxin, 0.4 ng neurotoxin, 0.5 ng neurotoxin, 0.6 ng neurotoxin, 0.7 ng neurotoxin, 0.8 ng neurotoxin, 0.9 ng neurotoxin, 1.0 ng neurotoxin, 1.1 ng neurotoxin, 1.2 ng neurotoxin, 1.3 ng neurotoxin, 1.4 ng neurotoxin, 1.5 ng neurotoxin, 1.6 ng neurotoxin, 1.7 ng neurotoxin, 1.8 ng neurotoxin, 1.9 ng neurotoxin, 2.0 ng neurotoxin, 2.1 ng neurotoxin, 2.2 ng neurotoxin, 2.3 ng neurotoxin, 2.4 ng neurotoxin, 2.5 ng neurotoxin, 2.6 ng neurotoxin, 2.7 ng neurotoxin, 2.8 ng neurotoxin, 2.9 ...9 ng neurotoxin, 2.1 ng neurotoxin, 2.2 ng neurotoxin, 2.3 ng neurotoxin, 2.4 ng neurotoxin, 2.5 ng neurotoxin, 2.6 ng neurotoxin, 2.7 ng neurotox The dose per administration may include .6ng neurotoxin, 2.7ng neurotoxin, 2.8ng neurotoxin, 2.9ng neurotoxin, 3.0ng neurotoxin, 3.1ng neurotoxin, 3.2ng neurotoxin, 3.3ng neurotoxin, 3.4ng neurotoxin, 3.5ng neurotoxin, 3.6n neurotoxin, 3.7n neurotoxin, 3.8n neurotoxin, 3.9ng neurotoxin, 4.0ng neurotoxin, 4.1ng neurotoxin, 4.2ng neurotoxin, 4.3ng neurotoxin, 4.4ng neurotoxin, 4.5ng neurotoxin, 5ng neurotoxin, 6ng neurotoxin, 7ng neurotoxin, 8ng neurotoxin, 9ng neurotoxin, 10ng neurotoxin, and the like.
[0078] Ultimately, however, both the amount of toxin administered and its frequency of administration are at the discretion of the treating physician, commensurate with concerns about safety and effects caused by the toxin.
[0079] Embodiments include injection of a volume of dermal filler (e.g., hyaluronic acid). In embodiments, the volume of the hyaluronic acid composition includes, for example, 0.3ml, 0.4ml, 0.5ml, 0.6ml, 0.7ml, 0.8ml, 0.9ml, 1ml, 1.5ml, 2ml, 2.5ml, 3ml, 3.5ml, 4ml, 4.5ml, 5ml, 5.5ml, 6ml, 6.5ml, 7ml, 7.5ml, 8ml, 8.5ml, 9ml, 9.5ml, 10ml, 12ml, 14ml, 16ml, 18ml, 20ml, 22ml, 24ml, 26ml, 27ml, 28ml, 29ml, 30ml, etc.
[0080] In embodiments, the volume of the dermal filler composition includes, for example, 0.3 ml or less, 0.4 ml or less, 0.5 ml or less, 0.6 ml or less, 0.7 ml or less, 0.8 ml or less, 0.9 ml or less, 1 ml or less, 1.5 ml or less, 2 ml or less, 2.5 ml or less, 3 ml or less, 3.5 ml or less, 4 ml or less, 4.5 ml or less, 5 ml or less, 5.5 ml or less, 6 ml or less, 6.5 ml or less, 7 ml or less, 7.5 ml or less, 8 ml or less, 8.5 ml or less, 9 ml or less, 9.5 ml or less, 10 ml or less, 12 ml or less, 14 ml or less, 16 ml or less, 18 ml or less, 20 ml or less, 22 ml or less, 24 ml or less, 26 ml or less, 27 ml or less, 28 ml or less, 29 ml or less, 30 ml or less, etc.
[0081] In embodiments, the volume of the dermal filler composition includes, for example, 0.3 ml or more, 0.4 ml or more, 0.5 ml or more, 0.6 ml or more, 0.7 ml or more, 0.8 ml or more, 0.9 ml or more, 1 ml or more, 1.5 ml or more, 2 ml or more, 2.5 ml or more, 3 ml or more, 3.5 ml or more, 4 ml or more, 4.5 ml or more, 5 ml or more, 5.5 ml or more, 6 ml or more, 6.5 ml or more, 7 ml or more, 7.5 ml or more, 8 ml or more, 8.5 ml or more, 9 ml or more, 9.5 ml or more, 10 ml or more, 12 ml or more, 14 ml or more, 16 ml or more, 18 ml or more, 20 ml or more, 22 ml or more, 24 ml or more, 26 ml or more, 27 ml or more, 28 ml or more, 29 ml or more, 30 ml or more, etc.
[0082] In embodiments, the one or more treatment devices applying the charge, electric field, or current may be administered for, for example, 30 seconds, 45 seconds, 60 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 21 minutes, 22 minutes, 23 minutes, 24 minutes, 25 minutes, 26 minutes, 27 minutes, 28 minutes, 29 minutes, 30 minutes, 31 minutes, 32 minutes, 33 minutes, 34 minutes, 35 minutes, 36 minutes, 37 minutes, 38 minutes, 39 minutes, 40 minutes, 41 minutes, 42 minutes, 43 minutes, 44 minutes, 45 minutes, 46 minutes, 47 minutes, 48 minutes, 49 minutes, 50 minutes, 51 minutes, 52 minutes, 53 minutes, 54 minutes, 55 minutes, 56 minutes, 57 minutes, 58 minutes, 59 minutes, 60 minutes, 61 minutes, 62 minutes minutes, 63 minutes, 63 minutes, 64 minutes, 65 minutes, 66 minutes, 67 minutes, 68 minutes, 69 minutes, 70 minutes, 71 minutes, 72 minutes, 73 minutes, 74 minutes, 75 minutes, 76 minutes, 77 minutes, 78 minutes, 79 minutes, 80 minutes, 81 minutes, 82 minutes, 83 minutes, 84 minutes, 85 minutes, 86 minutes, 87 minutes, 88 minutes, 89 minutes, 90 minutes, 91 minutes, 92 minutes, 93 minutes, 94 minutes, 95 minutes, 96 minutes, 97 minutes, such as for 98 minutes, 99 minutes, 100 minutes, 101 minutes, 102 minutes, 103 minutes, 104 minutes, 105 minutes, 106 minutes, 107 minutes, 108 minutes, 109 minutes, 110 minutes, 111 minutes, 112 minutes, 113 minutes, 114 minutes, 115 minutes, 116 minutes, 117 minutes, 118 minutes, 119 minutes, 120 minutes, or longer, applied around or to the treatment area.
[0083] In embodiments, the one or more treatment devices applying the charge, electric field, or current may be applied for, for example, 30 seconds or more, 45 seconds or more, 60 seconds or more, 1 minute or more, 2 minutes or more, 3 minutes or more, 4 minutes or more, 5 minutes or more, 6 minutes or more, 7 minutes or more, 8 minutes or more, 9 minutes or more, 10 minutes or more, 11 minutes or more, 12 minutes or more, 13 minutes or more, 14 minutes or more, 15 minutes or more, 16 minutes or more, 17 minutes or more, 18 minutes or more, 19 minutes or more, 20 minutes or more, 21 minutes or more, 22 minutes or more, 23 minutes or more, 24 minutes or more, 25 minutes or more, 26 minutes or more, ,27 minutes or more,28 minutes or more,29 minutes or more,30 minutes or more,31 minutes or more,32 minutes or more,33 minutes or more,34 minutes or more,35 minutes or more,36 minutes or more,37 minutes or more,38 minutes or more,39 minutes or more,40 minutes or more,41 minutes or more,42 minutes or more,43 minutes or more,44 minutes or more,45 minutes or more,46 minutes or more,47 minutes or more,48 minutes or more,49 minutes or more,50 minutes or more,51 minutes or more,52 minutes or more,53 minutes or more,54 minutes or more,55 minutes or more,56 minutes or more,57 minutes or more,58 minutes or more,59 minutes or more,60 minutes or more,6 1 minute or more, 62 minutes or more, 63 minutes or more, 64 minutes or more, 65 minutes or more, 66 minutes or more, 67 minutes or more, 68 minutes or more, 69 minutes or more, 70 minutes or more, 71 minutes or more, 72 minutes or more, 73 minutes or more, 74 minutes or more, 75 minutes or more, 76 minutes or more, 77 minutes or more, 78 minutes or more, 79 minutes or more, 80 minutes or more, 81 minutes or more, 82 minutes or more, 83 minutes or more, 84 minutes or more, 85 minutes or more, 86 minutes or more, 87 minutes or more, 88 minutes or more, 89 minutes or more, 90 minutes or more, 91 minutes or more, 92 minutes or more, 93 minutes or more, 94 minutes or more, 95 minutes or longer, such as for 96 minutes or more, 97 minutes or more, 98 minutes or more, 99 minutes or more, 100 minutes or more, 101 minutes or more, 102 minutes or more, 103 minutes or more, 104 minutes or more, 105 minutes or more, 106 minutes, 107 minutes or more, 108 minutes or more, 109 minutes or more, 110 minutes or more, 111 minutes or more, 112 minutes or more, 113 minutes or more, 114 minutes or more, 115 minutes or more, 116 minutes or more, 117 minutes or more, 118 minutes or more, 119 minutes or more, 120 minutes or more, or longer.
[0084] In embodiments, the one or more treatment devices applying the charge, electric field, or current may be administered for, e.g., 30 seconds or less, 45 seconds or less, 60 seconds or less, 1 minute or less, 2 minutes or less, 3 minutes or less, 4 minutes or less, 5 minutes or less, 6 minutes or less, 7 minutes or less, 8 minutes or less, 9 minutes or less, 10 minutes or less, 11 minutes or less, 12 minutes or less, 13 minutes or less, 14 minutes or less, 15 minutes or less, 16 minutes or less, 17 minutes or less, 18 minutes or less, 19 minutes or less, 20 minutes or less, 21 minutes or less, 22 minutes or less, 23 minutes or less, 24 minutes or less, 25 minutes or less, 26 minutes or less, Below, 27 minutes or less, 28 minutes or less, 29 minutes or less, 30 minutes or less, 31 minutes or less, 32 minutes or less, 33 minutes or less, 34 minutes or less, 35 minutes or less, 36 minutes or less, 37 minutes or less, 38 minutes or less, 39 minutes or less, 40 minutes or less, 41 minutes or less, 42 minutes or less, 43 minutes or less , 44 minutes or less, 45 minutes or less, 46 minutes or less, 47 minutes or less, 48 minutes or less, 49 minutes or less, 50 minutes or less, 51 minutes or less, 52 minutes or less, 53 minutes or less, 54 minutes or less, 55 minutes or less, 56 minutes or less, 57 minutes or less, 58 minutes or less, 59 minutes or less, 60 minutes or less, 6 1 minute or less, 62 minutes or less, 63 minutes or less, 64 minutes or less, 65 minutes or less, 66 minutes or less, 67 minutes or less, 68 minutes or less, 69 minutes or less, 70 minutes or less, 71 minutes or less, 72 minutes or less, 73 minutes or less, 74 minutes or less, 75 minutes or less, 76 minutes or less, 77 minutes or less, 78 minutes or less, 79 minutes or less, 80 minutes or less, 81 minutes or less, 82 minutes or less, 83 minutes or less, 84 minutes or less, 85 minutes or less, 86 minutes or less, 87 minutes or less, 88 minutes or less, 89 minutes or less, 90 minutes or less, 91 minutes or less, 92 minutes or less, 93 minutes or less, 94 minutes or less, 95 minutes or less or less, 96 minutes or less, 97 minutes or less, 98 minutes or less, 99 minutes or less, 100 minutes or less, 101 minutes or less, 102 minutes or less, 103 minutes or less, 104 minutes or less, 105 minutes or less, 106 minutes or less, 107 minutes or less, 108 minutes or less, 109 minutes or less, 110 minutes or less, 111 minutes or less, 112 minutes or less, 113 minutes or less, 114 minutes or less, 115 minutes or less, 116 minutes or less, 117 minutes or less, 118 minutes or less, 119 minutes or less, 120 minutes or less, or longer, etc., applied around or to the treatment area.
[0085] In embodiments, the attracting / repulsive charge, projected, or current is applied to the treatment site and around the treatment site. For example, in embodiments, the electrodes are powered, for example, by 1-10V, and applied approximately 1 cm apart, with the attracting electrode applied over the treatment site and the repulsive electrode applied to form a partial or complete perimeter around the treatment site. The distance between the attracting and repulsive electrodes can be determined based on the voltage applied to provide the most beneficial treatment. For example, the attracting and repulsive electrodes can be spaced 1 mm apart, 2 mm apart, 3 mm apart, 4 mm apart, 5 mm apart, 6 mm apart, 7 mm apart, 8 mm apart, 9 mm apart, 10 mm apart, 11 mm apart, 12 mm apart, 13 mm apart, 14 mm apart, 15 mm apart, 16 mm apart, 17 mm apart, 18 mm apart, 19 mm apart, 2 cm apart, 2.5 cm apart, 3 cm apart, 3.5 cm apart, 4 cm apart, 4.5 cm apart, 5 cm apart, 5.5 cm apart, 6.5 cm apart, 7.5 cm apart, 8.5 cm apart, 9.5 cm apart, 10.5 mm apart, 11 mm apart, 12 mm apart, 13 mm apart, 14 mm apart, 15 mm apart, 16 mm apart, 17 mm apart, 18 mm apart, 19 mm apart, 2 cm apart, 2.5 cm apart, 3 cm apart, 3.5 cm apart, 4 cm apart, 4.5 cm apart, 5 cm apart, 5. ... Such distances may be applied at .5cm apart, 6cm apart, 6.5cm apart, 7cm apart, 7.5cm apart, 8cm apart, 8.5cm apart, 9cm apart, 10cm apart, 10.5cm apart, 11cm apart, 11.5cm apart, 12cm apart, 12.5cm apart, 13cm apart, 13.5cm apart, 14cm apart, 14.5cm apart, 15cm apart, 15.5cm apart, 16cm apart, 16.5cm apart, 17cm apart or greater distances.
[0086] In embodiments, the distance between the attracting and repelling electrodes may be, for example, at least 1 mm apart, at least 2 mm apart, at least 3 mm apart, at least 4 mm apart, at least 5 mm apart, at least 6 mm apart, at least 7 mm apart, at least 8 mm apart, at least 9 mm apart, at least 10 mm apart, at least 11 mm apart, at least 12 mm apart, at least 13 mm apart, at least 14 mm apart, at least 15 mm apart, at least 16 mm apart, at least 17 mm apart, at least 18 mm apart, at least 19 mm apart, at least 2 cm apart, at least 2.5 cm apart, at least 3 cm apart, at least 3.5 cm apart, at least 4 cm apart, at least 4.5 cm apart. , at least 5 cm apart, at least 5.5 cm apart, at least 6 cm apart, at least 6.5 cm apart, at least 7 cm apart, at least 7.5 cm apart, at least 8 cm apart, at least 8.5 cm apart, at least 9 cm apart, at least 10 cm apart, at least 10.5 cm apart, at least 11 cm apart, at least 11.5 cm apart, at least 12 cm apart, at least 12.5 cm apart, at least 13 cm apart, at least 13.5 cm apart, at least 14 cm apart, at least 14.5 cm apart, at least 15 cm apart, at least 15.5 cm apart, at least 16 cm apart, at least 16.5 cm apart, at least 17 cm apart, or even longer distances.
[0087] In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, 1 mm or less apart, 2 mm or less apart, 3 mm or less apart, 4 mm or less apart, 5 mm or less apart, 6 mm or less apart, 7 mm or less apart, 8 mm or less apart, 9 mm or less apart, 10 mm or less apart, 11 mm or less apart, 12 mm or less apart, 13 mm or less apart, 14 mm or less apart, 15 mm or less apart, 16 mm or less apart, 17 mm or less apart, 18 mm or less apart, 19 mm or less apart, 2 cm or less apart, 2.5 cm or less apart, 3 cm or less apart, 3.5 cm or less apart, 4 cm or less apart, 4.5 cm or less apart, 5 cm or less apart, 5.5 cm or less apart, 6 cm or less apart, 6.5 cm or less apart, 7 cm or less apart, 7.5 cm or less apart, 8 cm or less apart, 8.5 cm or less apart, 9 cm or less apart, 10 cm or less apart, 10.5 cm or less apart, 11 cm or less apart, 11.5 cm or less apart, 12 cm or less apart, 12.5 cm or less apart, 13 cm or less apart, 13.5 cm or less apart, 14 cm or less apart, 14.5 cm or less apart, 15 cm or less apart, 15.5 cm or less apart, 16 cm or less apart, 16.5 cm or less apart, 17 cm or less apart, or even longer distances.
[0088] In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, 1 to 20 mm, 2 to 18 mm, 4 to 16 mm, 6 to 14 mm, 8 to 12 mm, etc. In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, 1 to 10 mm, 1 to 9 mm, 1 to 8 mm, 1 to 7 mm, 1 to 6 mm, 1 to 5 mm, 1 to 4 mm, 1 to 3 mm, 1 to 2 mm, etc. In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, 2 to 10 mm, 2 to 9 mm, 2 to 8 mm, 2 to 7 mm, 2 to 6 mm, 2 to 5 mm, 2 to 4 mm, 2 to 3 mm, etc.
[0089] In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, at least 1 mm to 20 mm, at least 2 mm to 18 mm, at least 4 mm to 16 mm, at least 6 mm to 14 mm, at least 8 mm to 12 mm, etc. In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, at least 1 mm to 10 mm, at least 1 mm to 9 mm, at least 1 mm to 8 mm, at least 1 mm to 7 mm, at least 1 mm to 6 mm, at least 1 mm to 5 mm, at least 1 mm to 4 mm, at least 1 mm to 3 mm, at least 1 mm to 2 mm, etc. In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, at least 2 mm to 10 mm, at least 2 mm to 9 mm, at least 2 mm to 8 mm, at least 2 mm to 7 mm, at least 2 mm to 6 mm, at least 2 mm to 5 mm, at least 2 mm to 4 mm, at least 2 mm to 3 mm, etc.
[0090] In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, 1 mm or less to 20 mm, 2 mm or less to 18 mm, 4 mm or less to 16 mm, 6 mm or less to 14 mm, 8 mm or less to 12 mm, etc. In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, 1 mm or less to 10 mm, 1 mm or less to 9 mm, 1 mm or less to 8 mm, 1 mm or less to 7 mm, 1 mm or less to 6 mm, 1 mm or less to 5 mm, 1 mm or less to 4 mm, 1 mm or less to 3 mm, 1 mm or less to 2 mm, etc. In an embodiment, the distance between the attracting electrode and the repelling electrode may be, for example, 2 mm or less to 10 mm, 2 mm or less to 9 mm, 2 mm or less to 8 mm, 2 mm or less to 7 mm, 2 mm or less to 6 mm, 2 mm or less to 5 mm, 2 mm or less to 4 mm, 2 mm or less to 3 mm, etc.
[0091] In embodiments, the disclosed devices may include circular or "donut" shaped devices (including a void in the center) that include electrodes that generate a repulsive field (e.g., an electric field). For example, the disclosed devices may include electrodes that generate a repulsive electric field that can apply the void directly to the treatment site and over the device body surrounding the treatment site. This type of embodiment would be particularly suitable for use with treatments where diffusion of the injected material is not desired. For example, in methods that include administration of neurotoxins to the patient's head, for example for the treatment of migraines or depression or pain, the disclosed devices can be applied prior to injection, and then the injection is performed through the void area.
[0092] The disclosed compositions suitable for use with the disclosed devices can include cosmetic pharmaceutical compositions such as dermal fillers. EXAMPLES
[0093] 1) Use of electric fields to minimize diffusion of neurotoxins A 44 year old male patient is scheduled to be treated with BoNT / A to minimize glabellar lines. Prior to administering the toxin via needle injection, the physician applies a disclosed embodiment that creates a positive electric field within 10 mm surrounding the intended injection site. The physician then uses 4 U of BoNT / A at a typical glabellar line treatment site and injects into 5 sites. The patient wears the embodiment that creates the positive electric field for 3 hours. The patient does not experience ptosis.
[0094] 2) Use of electric fields to minimize diffusion of neurotoxins A 49 year old male patient is scheduled to be treated with BoNT / E to minimize glabellar lines. Prior to administering the toxin via needle injection, the physician applies a disclosed embodiment that creates a positive electric field within 10 mm surrounding the intended injection site. The physician then uses 4 U of BoNT / E at a typical glabellar line treatment site and injects into 5 sites. The patient wears the embodiment that creates the positive electric field for 3 hours. The patient does not experience ptosis.
[0095] 3) Use of electric fields to minimize the diffusion of neurotoxins A 32 year old female patient is scheduled to be treated with BoNT / B to minimize glabellar lines. Prior to administering the toxin via needle injection, the physician applies a disclosed embodiment that creates a positive electric field within 10 mm surrounding the intended injection site. The physician then uses 4 U of BoNT / B at a typical glabellar line treatment site and injects into 5 sites. The patient wears the embodiment that creates the positive electric field for 3 hours. The patient does not experience ptosis.
[0096] 4) Use of electric fields to minimize the diffusion of neurotoxins A 27-year-old male patient is scheduled to be treated with BoNT / A to minimize glabellar lines. Prior to administering the toxin via needle injection, the physician applies a disclosed embodiment including platinum electrodes powered by a 5V power supply that creates a positive electric field within 10mm surrounding the intended injection site. The physician then uses 4U of BoNT / A at a typical glabellar line treatment site and injects into 5 sites. The patient wears the embodiment that creates the positive electric field for 3 hours. The patient does not experience ptosis.
[0097] 5) Use of electric fields to minimize diffusion of neurotoxins A 27-year-old male patient is scheduled to be treated with BoNT / A to minimize glabellar lines. Prior to administering the toxin via needle injection, the physician applies a disclosed embodiment including platinum electrodes powered by a 3V power supply that creates a positive electric field within 10mm surrounding the intended injection site. The physician then uses 4U of BoNT / A at a typical glabellar line treatment site and injects into 5 sites. The patient wears the embodiment that creates the positive electric field for 3 hours. The patient does not experience ptosis.
[0098] 6) Use of electric fields to minimize diffusion of neurotoxins A 33-year-old female patient is scheduled to be treated with BoNT / A to minimize crow's feet. Prior to administering the toxin via needle injection, the physician applies a disclosed embodiment including a zinc electrode that creates a circumferential positive electric field surrounding the intended injection site. The physician then uses 4 U of BoNT / A at a typical crow's feet treatment site and injects into 5 sites. After injection, the physician applies a disclosed embodiment including a silver electrode that creates a negative electric field directly above the injection site. The patient wears the embodiment that creates the positive and negative electric fields for 30 minutes. The patient does not experience ptosis.
[0099] 7) Use of electric fields to minimize diffusion of neurotoxins A 54-year-old female patient is scheduled to be treated with BoNT / A to minimize crow's feet. Prior to administering the toxin via needle injection, the physician applies a disclosed embodiment including a zinc electrode that creates a circumferential positive electric field surrounding the intended injection site. The physician then injects 5 sites with 5 U of BoNT / E at a typical crow's feet treatment site. After injection, the physician applies a disclosed embodiment including a silver electrode that creates a negative electric field directly above the injection site. The patient wears the embodiment that creates the positive and negative electric fields for 30 minutes. The patient does not experience ptosis.
[0100] 7) Use of electric fields to minimize diffusion of neurotoxins A 33 year old female patient is scheduled to be treated with BoNT / B to minimize crow's feet. Prior to administering the toxin via needle injection, the physician applies a disclosed embodiment that creates a circumferential positive electric field surrounding the intended injection site. The physician then injects 5 sites with 4U of BoNT / B into a typical crow's feet treatment site. After injection, the physician applies a disclosed embodiment that creates a negative electric field directly above the 5 injection sites. The patient wears the embodiment that creates the positive and negative electric fields for 30 minutes three times. The patient does not experience diffusion of the toxin from the treatment site.
[0101] 8) Use of Electric Fields to Minimize Diffusion of Dermal Fillers A 54 year old male patient is scheduled to be treated with hyaluronic acid. Prior to administering the filler via needle injection, the physician applies a disclosed embodiment that creates a circumferential negative electric field surrounding the intended injection site. The patient wears the embodiment that creates a positive electric field for three hours. The patient experiences no spreading of the filler.
[0102] 9) Use of Electric Fields to Minimize Diffusion of Dermal Fillers A 43 year old female patient is scheduled to be treated with hyaluronic acid. Prior to administering the filler via needle injection, the physician applies a disclosed embodiment that creates a circumferential negative electric field surrounding the intended injection site. After injection, the physician applies a disclosed embodiment that creates a positive electric field directly above the injection site. The patient wears the embodiment that creates the positive and negative electric fields for 30 minutes. The patient does not experience any spreading of the filler.
[0103] 10) Use of TENS to minimize the spread of dermal fillers A 33-year-old female patient is scheduled to be treated with BoNT / A to minimize crow's feet. Prior to administering the toxin via needle injection, the physician applies a TENS device to minimize diffusion of the neurotoxin. Prior to injection, the positive pole of the TENS is applied to repel the toxin out of the treatment area, while the negative pole is placed directly over the injection site. The intensity of the TENS is increased until the patient reports a tingling sensation.
[0104] In summary, although aspects of the present specification are highlighted by reference to specific embodiments, it will be appreciated that those skilled in the art will readily appreciate that these disclosed embodiments are merely illustrative of the principles of the subject matter disclosed herein. It is therefore to be understood that the disclosed subject matter is in no way limited to the specific methodology, protocols, and / or reagents, etc. described herein. Thus, various modifications, or alterations, or alternative configurations of the disclosed subject matter can be made in accordance with the teachings of the present specification without departing from the spirit of the specification. Finally, the terms used herein are for the purpose of describing specific embodiments only, and are not intended to limit the scope of the present disclosure, which is defined solely by the claims. Thus, the embodiments of the present disclosure are not limited to those precisely as shown and described.
[0105] Certain embodiments are described herein, including the best mode known to the inventors for carrying out the methods and devices described herein. Of course, variations of these described embodiments will become apparent to those skilled in the art upon reading the above description. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described embodiments in all possible variations thereof is encompassed by this disclosure, unless otherwise noted herein or clearly contradicted by context.
[0106] Groupings of alternative embodiments, elements, or steps of the present disclosure should not be construed as limiting. Each group member may be referred to and claimed individually or in any combination with other group members disclosed herein. It is anticipated that one or more members of a group may be included in or deleted from a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification includes the group as modified, and thus is deemed to satisfy the recitation requirements of all Markush groups used in the appended claims.
[0107] Unless otherwise indicated, all numbers expressing features, items, quantities, parameters, characteristics, terms, etc. used in the present specification and claims should be understood in all cases as being modified by the term "about". As used herein, the term "about" means that the feature, item, quantity, parameter, characteristic, or term so qualified encompasses a range of ±10% above or below the value of the described feature, item, quantity, parameter, characteristic, or term. Thus, unless otherwise indicated to the contrary, the numerical parameters described in this specification and the appended claims are approximations that may vary. At the very least, and not intended to limit the application of the doctrine of equivalents to the scope of the claims, each numerical indication should at least be interpreted in light of the number of reported significant digits and by applying ordinary rounding techniques. The numerical ranges and values setting forth the broad scope of the present disclosure are approximations, however, the numerical ranges and values set forth in the specific examples are reported as precisely as possible. However, any numerical range or value inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. The recitation of numerical ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, and unless stated otherwise herein, each individual value of the numerical range is incorporated herein as if it were individually recited herein.
[0108] The terms "a," "an," "the," and similar referents used in the context of describing this disclosure (especially in the context of the claims below) should be construed to cover both the singular and the plural, unless otherwise stated herein or clearly contradicted by context. All methods described herein can be performed in any suitable order, unless otherwise stated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "etc.") provided herein is intended merely to better illuminate the disclosure and does not limit the scope of what is otherwise claimed. No language in this specification should be construed as indicating any non-claimed element essential to the practice of the embodiments disclosed herein.
[0109] Certain embodiments disclosed herein may be further limited in claims consisting of or consisting essentially of the language. When used in a claim, whether as filed or added by amendment, the transitional term "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional term "consisting essentially of" limits the claim to certain materials or steps, as well as those that do not materially affect the basic and novel characteristics. An embodiment of the present disclosure so claimed is essentially or expressly described and enabled herein.
Claims
1. A medical device used to localize a subcutaneously injected charged active agent at a treatment site at a depth of 1 to 15 mm, comprising: a) a repulsion electrode at the skin surface that generates a positive charge if the isoelectric point of the charged active agent is greater than 7.4 and a negative charge if the isoelectric point of the charged active agent is less than 7.4; b) an attractor electrode on the skin surface that generates a negative charge if the isoelectric point of the charged active agent is greater than 7.4 and generates a positive charge if the isoelectric point of the charged active agent is less than 7.4; Including, 1. A medical device comprising: a skin surface repulsion electrode and a skin surface attraction electrode that are electrically conductive between the skin surface repulsion electrode and the skin surface attraction electrode, the skin surface repulsion electrode and the skin surface attraction electrode being positioned to localize the subcutaneously injected charged active agent between the skin surface repulsion electrode and the skin surface attraction electrode.
2. The medical device of claim 1 , wherein the charged active agent comprises a neurotoxin.
3. The medical device of claim 2 , wherein the neurotoxin comprises a botulinum toxin.
4. The medical device of claim 3 , wherein the botulinum toxin comprises BoNT / A.
5. The medical device of claim 3 , wherein the botulinum toxin comprises BoNT / E.
6. The medical device of claim 3 , wherein the botulinum toxin comprises BoNT / B.
7. 10. The medical device of claim 1, wherein the charged active agent comprises hyaluronic acid in a dermal filler.
Citation Information
Patent Citations
topical drug formulation
JP2002511057A
Delivery of macromolecules into cells
JP2002535100A
Transdermal botulinum toxin composition
JP2005538082A
Cationic neurotoxin
JP2018502580A
flat plate electrode
JP2021529627A
